» Articles » PMID: 32372682

"Sick-but-not-dead": Multiple Paths to Catecholamine Deficiency in Lewy Body Diseases

Overview
Journal Stress
Publisher Informa Healthcare
Specialties Biology
Neurology
Date 2020 May 7
PMID 32372682
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Profound depletion of the catecholamines dopamine (DA) and norepinephrine in the brain, heart, or both characterizes Lewy body diseases such as Parkinson disease, dementia with Lewy bodies, and pure autonomic failure. Although one might presume that catecholamine deficiency in these disorders results directly and solely from loss of catecholaminergic neurons, there is increasing evidence that functional abnormalities in extant residual neurons contribute to the neurotransmitter deficiencies-the "sick-but-not-dead" phenomenon. This brief review highlights two such functional abnormalities-decreased vesicular sequestration of cytoplasmic catecholamines and decreased catecholamine biosynthesis. Another abnormality, decreased activity of aldehyde dehydrogenase, may have pathogenetic significance and contribute indirectly to the loss of catecholamine stores via interactions between the autotoxic catecholaldehyde 3,4-dihydroxyphenylacetaldehyde and the protein alpha-synuclein, which is a major component of Lewy bodies. Theoretically, chronically repeated stress responses could accelerate these abnormalities, via increased exocytosis and neuronal reuptake, which indirectly shifts tissue catecholamines from vesicular stores into the cytoplasm, and via increased tyrosine hydroxylation, which augments intra-cytoplasmic DA production. The discovery of specific paths mediating the sick-but-not-dead phenomenon offers novel targets for multi-pronged therapeutic approaches.

Citing Articles

Cardiac noradrenergic deficiency revealed by 18F-dopamine positron emission tomography identifies preclinical central Lewy body diseases.

Goldstein D, Holmes C, Sullivan P, Lopez G, Gelsomino J, Moore S J Clin Invest. 2023; 134(1).

PMID: 37883190 PMC: 10760969. DOI: 10.1172/JCI172460.


Neurotransmitters in Type 2 Diabetes and the Control of Systemic and Central Energy Balance.

Al-Sayyar A, Hammad M, Williams M, Al-Onaizi M, Abubaker J, Alzaid F Metabolites. 2023; 13(3).

PMID: 36984824 PMC: 10058084. DOI: 10.3390/metabo13030384.


Pathophysiological significance of increased α-synuclein deposition in sympathetic nerves in Parkinson's disease: a post-mortem observational study.

Isonaka R, Sullivan P, Goldstein D Transl Neurodegener. 2022; 11(1):15.

PMID: 35260194 PMC: 8905831. DOI: 10.1186/s40035-022-00289-y.


The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Goldstein D Int J Mol Sci. 2021; 22(11).

PMID: 34206133 PMC: 8199574. DOI: 10.3390/ijms22115999.

References
1.
Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H . Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 2005; 15(1):29-34. PMC: 8095848. DOI: 10.1111/j.1750-3639.2005.tb00097.x. View

2.
Lamotte G, Holmes C, Wu T, Goldstein D . Long-term trends in myocardial sympathetic innervation and function in synucleinopathies. Parkinsonism Relat Disord. 2019; 67:27-33. PMC: 7031858. DOI: 10.1016/j.parkreldis.2019.09.014. View

3.
Kordower J, Olanow C, Dodiya H, Chu Y, Beach T, Adler C . Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013; 136(Pt 8):2419-31. PMC: 3722357. DOI: 10.1093/brain/awt192. View

4.
Lohr K, Bernstein A, Stout K, Dunn A, Lazo C, Alter S . Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2014; 111(27):9977-82. PMC: 4103325. DOI: 10.1073/pnas.1402134111. View

5.
DelleDonne A, Klos K, Fujishiro H, Ahmed Z, Parisi J, Josephs K . Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol. 2008; 65(8):1074-80. DOI: 10.1001/archneur.65.8.1074. View